Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) reported second quarter 2026 net sales of $6.6 billion, up 9.4% as reported and 9.0% in constant currency, with organic net sales up 9.0%. MedSurg and Neurotechnology sales rose 9.7% to $3.6 billion, and Orthopaedics sales grew 9.1% to $3.0 billion.
Reported operating income margin was 25.2% and adjusted operating income margin(1) increased 170 bps to 27.4%. Reported EPS increased to $3.30, while adjusted EPS(1) rose 17.9% to $3.69. Net earnings were $1.3 billion, up 44.3%. Operating cash flow for the first half of 2026 was $1.8 billion, compared with $1.4 billion in 2025.
For full year 2026, Stryker now expects organic net sales growth(2) of 8.3%–9.3% and adjusted EPS(2) of $14.95–$15.10, including a modestly positive pricing impact and a slightly favorable expected foreign exchange effect if rates remain near current levels.
Stryker (NYSE: SYK) announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement on July 16, 2026. The system debuts the Mako Handheld Robotics platform, extending the Mako portfolio beyond robotic-arm assisted surgery into a new orthopaedic robotics category.
Mako RPS combines intraoperative planning with a robotically enabled saw and Stryker’s patented active adjustment technology, designed to respond to surgeons’ hand movements and help maintain alignment with the surgical plan. It is compatible with Stryker’s Triathlon Total Knee System and built to work with the Q Guidance System, expanding Stryker’s enabling technologies ecosystem.
Stryker (NYSE: SYK) will host a live webcast at 4:30 p.m. ET on Thursday, July 30, 2026 to discuss its second quarter 2026 financial results.
An accompanying earnings press release will be issued at approximately 4:05 p.m. ET, with both webcast and archive available on Stryker’s website.
Stryker (NYSE:SYK) announced a partnership with Major Champion golfer Shane Lowry as brand ambassador for its Joint Replacement division. Lowry, who supported his father through hip and knee replacements, will help spotlight the caregiver role in joint pain, surgery and recovery.
A global campaign across media, social and educational channels will focus on awareness, education and access to information for caregivers, encouraging proactive involvement from understanding treatment options to navigating recovery. Fans at the Travelers Championship can learn about joint pain treatment options in Stryker’s Fan Zone.
Stryker (NYSE:SYK) launched TPX HD, a premium small bone power tool for demanding orthopaedic procedures, including total joint revisions, minimally invasive surgery and oral maxillofacial cases.
The system offers up to 296% more torque and 40% faster performance* versus TPX Micro Drill at high speed, plus improved visibility, heat management and ergonomics.
Stryker (NYSE:SYK) launched its Pangea Plating System in Europe for treating a wide range of fracture patterns. The first European clinical case was completed at St. George's University Hospital in London.
The system offers anatomically focused plates, streamlined instrumentation, and variable-angle plating for fracture fixation across upper and lower extremities, and was developed with input from 26 orthopaedic surgeons using global anatomical data.
Stryker (NYSE:SYK) agreed to acquire Amplitude Vascular Systems for up to $835 million, in a pre-FDA exit backed by BioStar Capital. The deal is described as a milestone in expanding Stryker’s peripheral vascular portfolio with AVS’s hydraulic intravascular lithotripsy technology for calcified peripheral arterial disease.
Stryker (NYSE:SYK) completed the acquisition of Amplitude Vascular Systems on May 7, 2026, adding a next‑generation intravascular lithotripsy (IVL) platform for complex peripheral arterial disease.
The deal brings AVS’s CO₂‑generated pressure wave technology into Stryker’s peripheral vascular portfolio, intended to expand treatment options for challenging arterial disease and support physicians and patient outcomes.
Stryker (NYSE:SYK) Board declared a quarterly dividend of $0.88 per share, payable July 31, 2026, to shareholders of record at close on June 30, 2026. The dividend represents a 4.8% increase year-over-year and is unchanged from the prior quarter.
Stryker (NYSE:SYK) will present at the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026 at the Encore at Wynn Hotel in Las Vegas. The presentation by Spencer Stiles, Jason Beach and Nick Mead is scheduled for 1:40 p.m. PT.
A live webcast and replay will be available and archived on Stryker's Investor Relations website at www.stryker.com.